Centre for Research on Health and Social Care Management (Cergas), SDA Bocconi School of Management, Milan, Italy.
ARIA SpA (Azienda Regionale per L'Innovazione e gli Acquisti), Milan, Italy.
Breast Cancer Res Treat. 2020 Aug;183(1):189-199. doi: 10.1007/s10549-020-05748-6. Epub 2020 Jun 26.
Adjuvant endocrine therapy (AET) for ≥ 5 years is generally recommended for women with hormone receptor-positive breast cancer to reduce cancer recurrence/mortality; however, adherence can be suboptimal. We tested determinants of AET adherence using patient characteristics, treatment pathways, AET initiation timing, and multiple healthcare facility use. An underlying objective was to explore how oncological pathways mirror chronic disease management to monitor adherence and target improvement interventions using administrative datasets.
Using patient-linked administrative health data from the Italian Lombardy Region, we identified 33.291 surviving patients starting AET in 2010-2016, with two (22.939 patients) or five years (8400 patients) follow-up, using a ≥ 80% prescription refill approach to measure adherence and logistic regression to test determinants of adherence.
AET crude adherence falls significantly during follow-up, from 94% at 1 Year to 58% at 5 Years. At 5 Years, patients who were older (>70), prescribed tamoxifen-only (OR 0.69; 95% CI 0.57-0.83; p = 0.0001) vs. aromatase inhibitors-only or therapy switches, treated for depression (OR 0.68; 95% CI 0.60-0.78; p < 0.0001), with surgery performed in high-volume hospitals (OR 0.85; 95% CI 0.75-0.97; p = 0.0116) showed lower adherence. Loyalty, or continued care in the surgical hospital (OR 1.73; 95% CI 1.51-2.00; p < 0.0001), undergoing chemotherapy before AET (OR 2.65; 95% CI 2.02-3.48; p < 0.0001), and earlier AET initiation, positively influenced adherence.
Chronic disease monitoring using administrative data can help oncologists focus efforts to ensure AET adherence. Results suggest addressing mental health, age, disease severity patient perceptions, timely AET initiation and therapy switches, and encouraging continued follow-up in the same hospital or better care coordination with outside follow-up specialists.
辅助内分泌治疗(AET)通常建议用于激素受体阳性乳腺癌患者,以降低癌症复发/死亡率;然而,患者的依从性可能并不理想。我们使用患者特征、治疗途径、AET 起始时间和多次使用医疗保健设施等因素来检验 AET 依从性的决定因素。一个潜在的目标是探索肿瘤学途径如何反映慢性病管理,以使用行政数据集监测依从性并针对改善干预措施。
使用来自意大利伦巴第大区的患者链接行政健康数据,我们确定了 33291 名在 2010-2016 年开始 AET 的存活患者,随访时间为 2 年(22939 名患者)或 5 年(8400 名患者),采用≥80%处方补充方法测量依从性,并使用逻辑回归检验依从性的决定因素。
AET 的依从性在随访期间显著下降,从 1 年的 94%降至 5 年的 58%。在 5 年时,年龄较大(>70 岁)、仅服用他莫昔芬(OR 0.69;95%CI 0.57-0.83;p=0.0001)而非仅使用芳香化酶抑制剂或治疗转换、因抑郁症接受治疗(OR 0.68;95%CI 0.60-0.78;p<0.0001)、在高容量医院接受手术(OR 0.85;95%CI 0.75-0.97;p=0.0116)的患者依从性较低。忠诚度,即在手术医院持续接受治疗(OR 1.73;95%CI 1.51-2.00;p<0.0001)、在 AET 之前接受化疗(OR 2.65;95%CI 2.02-3.48;p<0.0001)和更早开始 AET,对依从性有积极影响。
使用行政数据进行慢性病监测可以帮助肿瘤学家集中精力确保 AET 依从性。结果表明,应解决心理健康、年龄、疾病严重程度、患者认知、及时开始 AET 和治疗转换,以及鼓励在同一家医院继续接受治疗或更好地与外部随访专家进行护理协调。